Journal
HUMAN MOLECULAR GENETICS
Volume 27, Issue R2, Pages R89-R98Publisher
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddy186
Keywords
-
Funding
- NIH [R01NS093357, R01NS095280, T32GM007250]
- New York Stem Cell Foundation
- National Multiple Sclerosis Society
- Pelizaeus Merzbacher Disease Foundation
- European Leukodystrophy Association
Ask authors/readers for more resources
Induced pluripotent stem cells (iPSCs) enable the generation of previously unattainable, scalable quantities of disease-relevant tissues from patients suffering from essentially any genetic disorder. This cellular material has proven instrumental for drug screening efforts on these disorders, and has facilitated the identification of novel therapeutics for patients. Here we will review the foundational technologies that have enabled iPSCs, the power and limitations of iPSC-based compound screens along with screening guidelines, and recent examples of screening efforts. Additionally we will provide a brief commentary on the future scientific roadmap using pluripotent-and 3D organoid-based, combinatorial approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available